Ranjana Advani

Clinical Trials

• Recruiting Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
• Not Recruiting Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
• Not Recruiting A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
• Not Recruiting Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
• Recruiting A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
• Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
• Not Recruiting Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
• Not Recruiting A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma
• Recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
• Recruiting Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy
• Recruiting Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
• Recruiting Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
• Recruiting Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
• Recruiting Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
• Recruiting A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
• Not Recruiting Rituximab in Treating Patients With Hodgkin's Lymphoma
• Not Recruiting An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study
• Not Recruiting An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
• Not Recruiting A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
• Not Recruiting AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
• Not Recruiting A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
• Not Recruiting A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
• Not Recruiting Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
• Not Recruiting Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy.
• Not Recruiting Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
• Not Recruiting Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
• Not Recruiting Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
• Not Recruiting Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A
• Not Recruiting Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
• Not Recruiting Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma
• Not Recruiting Clinical Trial of PXD101 in Patients With T-Cell Lymphomas
• Not Recruiting Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
• Not Recruiting S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
• Not Recruiting Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
• Not Recruiting Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
• Not Recruiting Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
• Not Recruiting A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
• Not Recruiting Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
• Not Recruiting A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
• Not Recruiting Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
• Not Recruiting A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
• Not Recruiting A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
• Not Recruiting A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
• Not Recruiting A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
• Not Recruiting Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
• Not Recruiting Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
• Not Recruiting Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
• Not Recruiting Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
• Not Recruiting A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
• Not Recruiting Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
• Not Recruiting A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
• Not Recruiting Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
• Not Recruiting Safety and Efficacy of PCI-32765 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
• Not Recruiting Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
• Not Recruiting A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
• Not Recruiting Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
• Not Recruiting A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
• Not Recruiting Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
• Not Recruiting Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
• Not Recruiting Phase 1 Trial of Oral Ixabepilone
• Not Recruiting Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
• Not Recruiting Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
• Not Recruiting Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma
• Not Recruiting Phase II Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides
• Not Recruiting Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
• Not Recruiting Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma
• Recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
• Recruiting Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
• Recruiting A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
• Recruiting Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
• Recruiting FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
• Recruiting Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
• Not Recruiting Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT